Tempus announces expansion of collaboration with takeda to leverage multimodal real-world datasets and biological model systems in oncology research and development

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announces an expansion to its collaboration with takeda (tse:4502/nyse:tak) that takes a data-first approach to research and development, with the aim of enhancing takeda's oncology research and development efforts. after an initial collaboration that leveraged tempus' de-identified multimodal datasets, this new agreement will expand upon.
TAK Ratings Summary
TAK Quant Ranking